Cardiovascular risk assessment and treatment in systemic lupus erythematosus

Area of Science:

• Rheumatology
• Cardiology
• Internal Medicine

Background:

• Systemic lupus erythematosus (SLE) survival rates have improved, leading to increased focus on comorbidities.
• Cardiovascular disease (CVD) is a leading cause of mortality in SLE patients.
• SLE patients experience premature atherosclerosis, driven by traditional risk factors, lupus-specific factors, and inflammation.

Purpose of the Study:

• To highlight the significant cardiovascular disease burden in SLE patients.
• To emphasize the need for comprehensive cardiovascular risk factor assessment and management in SLE.
• To advocate for integrating preventive cardiology into routine SLE care.

Main Methods:

• Review of existing literature on SLE and cardiovascular disease.
• Analysis of the interplay between traditional risk factors, SLE-specific factors, and inflammation in atherosclerosis development.
• Comparison of current SLE patient risk assessment with standards for known cardiovascular disease patients.

Main Results:

• SLE patients exhibit accelerated atherosclerosis development.
• Traditional cardiovascular risk factors are often under-evaluated in SLE patients.
• Inflammatory mediators and lupus-specific factors contribute significantly to CVD risk in SLE.

Conclusions:

• Preventive cardiology should be a cornerstone of SLE management.
• SLE patients require systematic cardiovascular risk assessment and intervention comparable to those with established CVD.
• Proactive management of modifiable risk factors can mitigate premature CVD in SLE.